US EditionPublished • loading... • Updated
Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program
Novartis pays $2 billion upfront for SNV4818, a phase 1/2 pan-mutant selective PI3Kα inhibitor aiming for better tolerability and combination use in breast cancer treatment.
- This year Novartis agreed to buy Synnovation Therapeutics' Pikavation Therapeutics and SNV4818, paying $2 billion upfront plus up to $1 billion in milestones with closing expected in the first half.
- Clinical need for better-tolerated PI3K therapies is driven by roughly 40% of HR-positive, HER2-negative breast cancer patients harboring PIK3CA mutations and toxicity warnings limiting existing PI3Kα inhibitors.
- Preclinical and early clinical data show SNV4818 has strong activity against PIK3CA mutations and is in a Phase 1/2 study with fulvestrant and palbociclib, results due 2027.
- The move follows pressure on Piqray from Roche's Itovebi, and Novartis shares were down 1.02% at $146.68 at publication.
- If trials succeed, SNV4818 could improve tolerability, enable earlier combinations, and expand options, aligning with Novartis' precision-medicine and oncology growth strategy including Kisqali.
Insights by Ground AI
19 Articles
19 Articles
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug - Novartis (NYSE:NVS)
Novartis AG (NYSE:NVS) on Friday agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics, aiming to strengthen its breast cancer pipeline with a more targeted and potentially better-tolerated treatment approach. • Novartis stock is taking a breather. What should traders watch with NVS? Novartis Targets Next-Generation Breast Cancer Therapy The deal centers on SNV4818, an oral, pan-mutant–selective PI3Kα inhibito…
·New York, United States
Read Full Article
The business takes place less than a month after Novartis completes its larger purchase in a decade — purchase by the neuromuscular drug developer Avidity Biosciences per US$ 12 billion
·Brazil
Read Full Article
Coverage Details
Total News Sources19
Leaning Left0Leaning Right4Center7Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
C 64%
R 36%
Factuality
To view factuality data please Upgrade to Premium
